FSL-1, a bacterial-derived toll-like receptor 2/6 agonist, enhances resistance to experimental HSV-2 infection

Table 2 FSL-1 application significantly protected against genital HSV-2 challenge in mice.

HSV-2 dose	FSL-1 2 μg 24 h prior^a		FSL-1 2 μg 6 h prior		DPBS vehicle control
(pfu)	%Infected^b	%Survival^c	%Infected	%Survival	%Infected	%Survival
1 × 10¹	ND^d	ND	ND	ND	30	70
1 × 10²	30	70	10^e	90	70	50
1 × 10³	50^e	50^e	100	40	100	0
1 × 10⁴	90	10	100	0	ND	ND
ID ₅₀ ^f	760 (80-7000)		260 (10-6000)		31 (10-80)
LD ₅₀ ^g	760 (80-7000)		660 (300-1000)		68 (7-700)

^a Intravaginal application of FSL-1 or DPBS vehicle control at indicated times prior to vaginal HSV-2 inoculation (n = 10 mice/treatment at each HSV-2 dose).
^b Percentage of mice with infectious virus in d2 vaginal swabs.
^c Percentage of mice that survived HSV-2 vaginal challenge up to d14 PI.
^d ND, not determined.
^e p < 0.05 compared to vehicle control (Fisher's exact test).
^f Dose of the virus required to infect 50% of the mice based on %Infected data; ID₅₀ (95% confidence interval).
^g Dose of the virus required to cause lethal outcomes in 50% of the mice based on % survival data; LD₅₀ (95% confidence interval).

ISSN: 1743-422X